This inventor holds 8 USPTO granted patents and 1 published patent application and 1 EPO patent. Top assignees: Shanghai Cancer Institute, Carsgen Therapeutics Limited, Other. Active years: 2006-2020.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Company Filing History:
6 out of 9 
1 out of 4 
1 out of 834,570 Years Active: 2006-2020
Title: Innovative Contributions of Shengli Yang in Cancer Research
Introduction
Shengli Yang, located in Shanghai, China, is a prominent inventor known for his significant contributions to the field of cancer research. With a total of eight patents, his innovative work focuses on developing advanced therapeutic methods for targeting specific tumor markers, particularly in the realm of immunotherapy.
Latest Patents
Among his latest patents, one notable invention is related to "Chimeric antigen receptors targeting GPC3 and uses thereof." This patent describes a nucleic acid that encodes a chimeric antigen receptor expressed on the surface of T lymphocytes. The receptor comprises specific components, including an extracellular binding domain made from a single chain antibody, scFv(GPC3), which selectively targets the C-terminal epitope of GPC3. Additionally, he developed a patent concerning the "Human epidermal growth factor receptor variant lacking an exon." This invention presents a variant of the epidermal growth factor receptor that promotes tumor cell invasion and metastasis, along with an encoding gene and a method for producing the variant through recombination technology.
Career Highlights
Shengli Yang has had a noteworthy career within leading research institutions and biotechnology companies. His significant tenure at the Shanghai Cancer Institute and Carsgen Therapeutics Limited showcases his commitment to pushing the frontiers of cancer treatment and research. His work often emphasizes the application of cutting-edge technology for therapeutic advancements.
Collaborations
Throughout his career, Yang has collaborated with accomplished professionals in the field, including esteemed colleagues Jianren Gu and Zonghai Li. These partnerships have enabled him to combine expertise and resources, driving forward innovation and research initiatives that aim to improve cancer therapies.
Conclusion
Shengli Yang embodies the spirit of innovation in the realm of medical research, particularly cancer therapeutics. His patents represent significant steps towards novel cancer treatments, reflecting his dedication to addressing critical issues in healthcare. As he continues to work on groundbreaking inventions, the impact of his contributions is likely to resonate through the medical community and beyond.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile